***In Vivo* Mitochondrial ATP Production Is Improved in Older Adult Skeletal Muscle After a Single Dose of Elamipretide in a Randomized Trial**

Baback Roshanravan¹, Sophia Z. Liu², Eric G. Shankland², John K. Amory⁴, H. Thomas
Robertson⁴, David J. Marcinek^{*2,5}, Kevin E. Conley^{2,5,6}

¹Department of Medicine, Division of Nephrology, University of California Davis, Davis,
CA; ²Translational Center for Metabolic Imaging, Department of Radiology,
³Department of Medicine, ⁴Department of Bioengineering, and ⁵Department of
Pathology, and ⁶Department of Physiology & Biophysics, University of Washington,
Seattle, WA

***Corresponding Author:**

David J. Marcinek, PhD
Professor of Radiology
Department of Bioengineering
University of Washington
Seattle, WA
Email: dmarc@uw.edu
Phone: 206-221-6785

1 **ABSTRACT**

2 **Background:** Loss of mitochondrial function contributes to fatigue, exercise intolerance

3 and muscle weakness, and is a key factor in the disability that develops with age and a

4 wide variety of chronic disorders. Here, we describe the impact of a first-in-class

5 cardiolipin-binding compound that is targeted to mitochondria and improves oxidative

6 phosphorylation capacity (Elamipretide, ELAM) in a randomized, double-blind, placebo-

7 controlled clinical trial.

8 **Methods:** Non-invasive magnetic resonance and optical spectroscopy provided measures

9 of mitochondrial capacity (ATP_{max}) with exercise and mitochondrial coupling (ATP

10 supply per O_2 uptake; P/O) at rest. The first dorsal interosseous (FDI) muscle was studied

11 in 39 healthy older adult subjects (60 to 85 yrs of age; 46% female) who were enrolled

12 based on the presence of poorly functioning mitochondria. We measured volitional

13 fatigue resistance by force-time integral over repetitive muscle contractions.

14 **Results:** A single ELAM dose elevated mitochondrial energetic capacity *in vivo* relative

15 to placebo (ΔATP_{max} ; $P=0.055$, $\% \Delta ATP_{max}$; $P=0.045$) immediately after a 2-hour

16 infusion. No difference was found on day 7 after treatment, which is consistent with the

17 half-life of ELAM in human blood. No significant changes were found in resting muscle

18 mitochondrial coupling. Despite the increase in ATP_{max} there was no significant effect of

19 treatment on fatigue resistance in the FDI.

20 **Conclusions:** These results highlight that ELAM rapidly and reversibly elevates

21 mitochondrial capacity after a single dose. This response represents the first

22 demonstration of a pharmacological intervention that can reverse mitochondrial

23 dysfunction *in vivo* immediately after treatment in aging human muscle.

24 **Keywords:** skeletal muscle, mitochondrial dysfunction, fatigue, endurance

1 Age and disease are associated with a debilitating loss of function that leads to
2 disability [1, 2], underlies morbidity [3] and has a substantial economic impact on
3 society, including the healthcare system [4]. Mitochondrial dysfunction is a key part of
4 the pathophysiology and reduced resilience associated with aging [5] and chronic disease
5 [6] in multiple organ systems. Mitochondrial dysfunction is also associated sarcopenia
6 and impaired physical endurance across multiple populations[7, 8]. This loss of muscle
7 function is an important contributor to reduced quality of life and increased morbidity
8 with age [9-11]. Despite observational data indicating the important role of mitochondria
9 in aging and disease there are no approved treatments that directly target dysfunctional
10 mitochondria in skeletal muscle. A new approach has emerged that targets dysfunctional
11 lipids, involves repair rather than replacement of deteriorated components [12, 13], and
12 acts rapidly after a single treatment to reverse dysfunction [14].

13 Elamipretide (ELAM) is a first-in-class compound that binds reversibly to the
14 phospholipid cardiolipin (CL) located within the inner mitochondrial membrane to
15 stabilizes its structure, promote cristae formation and curvature, and positively alters the
16 electrostatic environment [15, 16] [17, 18]. Early studies inaccurately described ELAM
17 as having antioxidant properties, [19-21] although more recent work has demonstrated
18 that ELAM actually reduces production of superoxide and H_2O_2 particularly where
19 overproduction resulted from dysfunctional mitochondria [22, 23]. Studies in isolated
20 mitochondria, cells and intact organs reveal improved ETC flux, reduced mitochondrial
21 generation of reactive oxygen species (ROS; H_2O_2), and elevated ATP generation with
22 ELAM treatment after ischemic insult and heart failure [16, 24, 25]. In skeletal muscle,
23 treatment with ELAM prevented the increase in mitochondrial oxidative stress and

1 muscle wasting associated with disuse atrophy in mouse hindlimb and diaphragm. In
2 aging mice a single IP injection of ELAM elevated the capacity to generate ATP,
3 improved the coupling of oxidative phosphorylation (P/O) in vivo, and increased fatigue
4 resistance in the tibialis anterior in old hindlimb muscle without affecting mitochondrial
5 energetics in young muscle [14]. Running endurance was also elevated in the old mice
6 after 8 days of daily injections of ELAM. More recently, an 8-week treatment with
7 ELAM demonstrated similar increases in *in vivo* mitochondrial energetics and fatigue
8 resistance in old mice, as well as a reversal of age-related redox stress[26]. It is
9 noteworthy that 4 month treatment of aged mice with ELAM reduced mtROS emission
10 and improved mitochondrial integrity in muscles from similar to the 8 week treatment,
11 but did not demonstrate a reduction in fiber atrophy nor improvements in force and
12 fatigue resistance in isolated muscles[26, 27], suggesting that improvements in
13 performance with ELAM treatment may be potentiated by systemic effects beyond the
14 myofiber fiber level. In a Phase 2 study 5 daily doses of ELAM increased the walking
15 distance over 6 minutes (Six-Minute Walk Test [6MWT]) ELAM in individuals with a
16 genetic mitochondrial myopathy [28], although the subsequent expanded Phase 3 trial
17 failed to detect a change in the 6 MWT. Thus, studies from both mouse models and
18 human disease indicate that both a better understanding of the effect of ELAM on *in vivo*
19 mitochondrial energetics and the link between mitochondrial energetics and skeletal
20 muscle function is necessary. Despite the trials focused on mitochondrial myopathy and
21 other human trials in heart disease, ischemia reperfusion, and ongoing trials in Barth and
22 mitochondrial associated vision disorders, there has been no direct measurement of
23 mitochondrial function in a human clinical trial to determine if the mechanism of action

1 of ELAM is mitochondrial in origin.

2 Here, we report the results from a randomized, double-blind, placebo controlled
3 clinical trial that evaluated the safety and efficacy of a single dose of ELAM on surrogate
4 endpoints of mitochondrial and muscle function in healthy older adults. Participants were
5 selected on the basis of having evidence of impaired in vivo muscle mitochondrial
6 energetics determined by dynamic, in vivo ³¹Phosphorus Magnetic Resonance
7 Spectroscopy using a using a standardized protocol [29, 30]. The effects on the first
8 dorsal interosseous (FDI) muscle of the hand was investigated for two reasons. First,
9 handgrip strength is an important clinical measure of frailty and disease burden strongly
10 associated with adverse health related outcomes across populations[31-34]. Second, this
11 particular muscle shows clear changes in mitochondrial function with age [29] providing
12 direct measurement of both mitochondrial energetics and muscle function
13 (Supplementary Figure S3). We hypothesized that ELAM infusion will lead to
14 immediate improvements in our primary surrogate endpoint, the maximal rate of ATP
15 production (ATP_{max})immediately after a 2-hour infusion of ELAM.. Two secondary
16 outcomes were evaluated: 1) the resting state coupling of oxidative phosphorylation
17 (ATP/O₂) to evaluate mechanisms of improvement and 2) exercise tolerance as evaluated
18 by muscle performance after ELAM treatment. Evidence of efficacy of mitochondrial
19 targeted therapeutics to improve muscle metabolism and function may guide future
20 therapeutic development and inform pharmacologic or lifestyle interventions targeting
21 improvements in quality of life in the older adults.

22

23

24

25

1 **METHODS**

2 Study Design and Participants

3 This randomized, double-blind, placebo-controlled trial was conducted at the University
4 of Washington Medical Center. Adults 60 to 85 years of age were recruited through
5 public lectures, mailers, and posted advertisements. Eligible participants were selected
6 based on two criteria found to be linked to low muscle function: 1) muscle mitochondrial
7 ATP synthesis capacity ($ATP_{max} < 0.7$ mM/sec) and 2) the coupling of oxidative
8 phosphorylation ($ATP \text{ synthesized per } O_2 \text{ uptake} \div 2 < 1.9$, [P/O]) [29, 30]. These fluxes
9 were assessed by *in vivo* magnetic resonance and optical spectroscopy (**Supplementary**
10 **Figures S1 and S2**) [29, 30]. Inclusion and exclusion criteria are listed in

11 **Supplementary Tables S1 and S2.** All procedures and protocols were in accordance
12 with the tenets of the declaration of Helsinki. The study protocol was approved by the
13 University of Washington Human Subjects Division and Western Institutional Review
14 Board (IRB00000533). All subjects provided written informed consent before entering
15 the trial. The study was registered with ClinicalTrials.gov (identifier: NCT02245620).

17 Power Calculations, Randomization, and Masking

19 The group size of 20 subjects each for treatment and placebo was based on a mean
20 change in P/O of 0.4 and standard deviation of ± 0.38 to provide a power of 0.9 at the
21 0.05 level of significance in healthy subjects 65 to 80 years of age[35]. An amended
22 protocol placed ATP_{max} as the primary outcome and P/O as the secondary outcome.
23 Randomization was performed at a 1:1 ratio by a computer-generated random sequence

1 using an Interactive Web-Response System (IWRS). Both participants and study
 2 personnel were blinded to treatment assignment during the duration of the study. ELAM
 3 was administered intravenously for 2 hours at 0.25 mg/kg body weight per hour, which is
 4 the level found to be both safe and effective in two human dose-escalation studies [28,
 5 36]. Placebo consisted of the vehicle used for the active drug, which contained
 6 preservative level concentrations of trehalose dihydrate, glutathione, and sodium
 7 hydroxide/acetic acid in physiological saline.

8

9 Outcomes

10 The primary endpoint was the change in *in vivo* skeletal muscle mitochondrial capacity
 11 (ATP_{max}) with exercise after 2 hours of infusion compared to baseline. The secondary
 12 endpoints were resting mitochondrial coupling (P/O) and exercise tolerance (force-time
 13 integral). The coupling of phosphorylation (ATP supply) to oxidation (O_2 uptake) by the
 14 mitochondria was expressed as P/O ($ATP/O_2 \div 2$). The change in muscle performance
 15 was measured as the sum of the muscle force (force-time integral, FTI) normalized to the
 16 maximum voluntary contraction (MVC) generated during voluntary contractions. This
 17 protocol involved step increases of contraction frequency starting at 60 contractions per
 18 minute [cpm] and increasing frequency 10 cpm each minute until exhaustion. Primary
 19 and secondary endpoints were reassessed 7 days post-infusion.

20

21 Study Procedures

22 The study consisted of 4 visits. A screening visit (Visit 1 or V1) determined eligibility
 23 and included a general health exam including ECG, blood tests, and non-invasive

measures of muscle mitochondrial energetics and exercise tolerance of the hand muscle (first dorsal interosseous [FDI], **Supplementary Figure S3**). Those found to qualify for the study returned within 28 days of V1, were infused with either placebo or drug, and all procedures were repeated immediately following infusion (Visit 2 or V2). The exercise tolerance test was repeated a day after the infusion (Visit 3 or V3). All procedures were repeated one week after infusion (Visit 4 or V4).

MRS/OS Protocol

The protocol for the phosphorus magnetic resonance spectroscopy (³¹P MRS) and optical spectroscopy (OS) has been previously published [29, 30]. These two spectroscopic measurements were made on the muscle during a period of ischemia. Probes for each measurement were placed at the same location on the skin surface of the FDI (**Supplementary Figure S3**). This allowed us to separate O₂ uptake from ATP flux in resting muscle *in vivo* (**Supplementary Figure S2**). P/O is a measure of the efficiency of ATP generation in resting muscle ($ATP/O_2 \div 2$). The mitochondrial oxidative phosphorylation capacity (ATP_{max}) was determined as described [30, 37]. Briefly, a short exercise bout involving the index finger was performed for a period of 20 to 30 seconds so that PCr was reduced by ~50%, while maintaining muscle pH>6.8. The PCr recovery was measured over 6 min to determine a time constant of recovery (t_{PCr}) to yield ATP_{max} ($= PCr_{rest} / t_{PCr}$) where $PCR_{rest} = 25.5$ mM. The ATP_{max} is the standard for characterizing mitochondrial ATP capacity *in vivo* and is directly related both to mitochondrial markers of oxidative phosphorylation and mitochondrial oxidation *in vivo*.

1 Muscle Performance Testing

2 Exercise tolerance was tested by measuring the sum of force generated by the FDI muscle
3 during repeated isometric contractions until exhaustion (**Supplementary Figure S3**). The
4 FDI is a model system for both energetic and mechanics measures [38] as well as
5 mitochondrial aging [29]. The maximum voluntary contraction (MVC) was measured as
6 the average of 3 maximum contractions separated by 5 sec and sustained for 3 sec each.
7 The exercise level was set at 70% of the MVC and the exercise began at a frequency of
8 60 contractions per minute (cpm) for the first minute. This frequency was increased at a
9 rate of 10 cpm with each minute until exhaustion. The FTI was measured as the sum of
10 the force generated by these contractions during the test and normalized to the subject's
11 MVC.

12

13 Statistical Analysis

14 The primary analysis set was the intent to treat study population. The primary endpoint
15 test was the difference in the mean change from baseline to immediately after infusion
16 between ELAM and the placebo group in a Student's t-test in an analysis of covariance
17 (ANCOVA) framework, with baseline as a covariate. The secondary endpoints (P/O and
18 FTI) were tested as a mean change from baseline between treatment groups immediately
19 after and 7 days post-infusion. Statistical tests were 2-sided and evaluated at the 0.05
20 level of significance. No adjustment for multiple comparisons was made per the pre-
21 specified statistical plan.

22

1 RESULTS

2 Participant Characteristics

3 Thirty-nine subjects, from 120 screened potential participants, were randomized to
 4 participate in the study based on overall good general health but presenting with low
 5 mitochondrial function ($\text{ATP}_{\text{max}} < 0.7 \text{ mM sec}^{-1}$ and $\text{P/O} < 1.9$) (**Figure 1**). Forty-seven
 6 subjects [39%] were excluded with high mitochondrial function, while 34 subjects [28%]
 7 were excluded due to clinical criteria. ATPmax data was not available for V2 for 1
 8 subject in both the PL and ELAM groups due to problems with data collection. An
 9 additional participant in the placebo group had an MRS result that did not meet our
 10 quality control criteria (motion artifact) after inclusion in the database; that scan was
 11 excluded from the analysis of the primary endpoint. A summary of the demographic and
 12 clinical assessments appears in **Table 1**.

13

14 Elevated ATP_{max}

15 The primary outcome of this study was an elevated ATP_{max} in the ELAM group versus
 16 the placebo group immediately after a 2-hour ELAM infusion ($P=0.055$ for delta
 17 ATPmax and $P=0.045$ for %change, **Figure 2A and B**). The values for ATPmax at
 18 baseline, immediate post-infusion, and 7 days after infusion, as well as the change values
 19 used in the ANCOVA analysis are reported in **Supplementary Table S3**. The mean
 20 increase from baseline to post-infusion was 27% in the in ELAM-treated subjects versus
 21 12% in the placebo-treated subjects (**Figure 2B**). In the ELAM group both post-infusion
 22 and 7-day ATPmax values were elevated above baseline, while only the post-infusion

ATPmax was higher than baseline in the placebo group ($P < 0.05$, paired t -test). However, the change in ATPmax at 7 days was not different between ELAM and PL groups.

Resting P/O

A secondary endpoint was the efficiency of oxidative phosphorylation (mitochondrial coupling or P/O), which is one mechanism that could underlie the increased phosphorylation rate with ELAM treatment. No change was seen in this secondary outcome of resting P/O (**Figure 3**). The baseline, post-infusion and 7-day measurements and ANCOVA analyses are shown in **Supplementary Table S4**. This stability of resting P/O indicates that the improvement in ATP_{max} was the result of higher flux through the ETC rather than more efficient synthesis of ATP per O₂ uptake. Thus, maximum flux through the ETC improved with ELAM treatment.

Muscle Function

Exercise tolerance in the hand muscle was a secondary endpoint that assessed the impact of ELAM infusion on muscle function. This endpoint was measured as the sum of force produced during continuous isometric contractions to exhaustion (FTI) normalized to peak strength (FTI per maximum voluntary contraction [MVC]) [38]. No change was apparent in the FTI relative to placebo post-infusion with ELAM in the ANCOVA analysis specified in the protocol (Fig. 4; **Supplementary Table S5**). However, post-hoc analyses suggest that the study was not sufficiently powered to detect a difference in muscle function in the full ANCOVA model. The ELAM group significantly increased relative to baseline ($P < 0.033$, paired t -test), while the placebo group did not ($P = 0.42$). In addition, a significant rise was found with the two additional days of testing (day 1 and

1 day 7 after infusion, $P < 0.04$) between ELAM versus placebo in ANOVA. In addition, a
 2 post-hoc analysis defining muscle fatigue by the number of contractions performed
 3 instead of FTI reduced within group variability and indicated a significant treatment
 4 effect with a two-way ANOVA (**Figure S4**).
 5

1 DISCUSSION

2 In a double-blind placebo-controlled randomized clinical trial a single 2-hour infusion of
3 ELAM improves *in vivo* ATP_{max} in the FDI over placebo in skeletal muscle of older
4 adults. Based on published materials that elucidated the mechanism of action of
5 elamipretide, it has been postulated that this significant change in ATP_{max} can be
6 attributed to the ability of elamipretide to reversibly bind to cardiolipin, resulting in
7 stabilization of the inner mitochondrial membrane and optimization of the electron
8 transport chain in dysfunctional mitochondria [39-41]. This rapid response of *in vivo*
9 ATP_{max} to a single ELAM dose in older adult humans reproduces results observed in old
10 mouse muscle using a similar MRS approach to measure mitochondrial function [14]. A
11 new insight that arose from this study is that the rise in ATP_{max} on the day of treatment
12 fades by day 7, which is consistent with the 16 hour half-time of ELAM in human blood
13 [36]. Thus, ELAM acted to elevate mitochondrial ATP generation capacity in a single
14 dose with a similar magnitude but much faster speed than prolonged interventions, such
15 as exercise, in human muscle from older adults.

16
17 In this study we specifically selected community-dwelling older adult participants who
18 demonstrated *in vivo* deficits in mitochondrial function to focus on the primary endpoint
19 of the study a priori defined as the change in ATP_{max} with ELAM treatment. Our
20 inclusion criteria included an ATP_{max} below 0.7 mM ATP/sec, which is above the mean
21 ATP_{max} of 0.5 - 0.6 mM ATP/sec from quadriceps muscle we have observed in previous
22 studies of older adults [9, 37, 42]. Previous work *in vivo* and *in vitro* suggests that some
23 of this decline in oxidative capacity in the skeletal muscle of older adults is due to poor

1 quality mitochondria as well as the loss of mitochondrial content with age. This is an
 2 important point because previous work in both mouse models and human subjects with
 3 genetic mitochondrial disease indicate that ELAM (SS-31) provides little or no benefit to
 4 well-functioning mitochondria [14, 26]. Despite the data described above, the extent and
 5 nature of mitochondrial dysfunction in aging skeletal muscle remains controversial with
 6 reports of no differences in oxidative capacity (ATP_{max}) or maximum respiration in vitro
 7 between older and young adult subjects. The disparity in findings between studies
 8 underscores heterogeneity of mitochondrial function with aging helping to explain the
 9 observation that nearly 40% of older adults screened for the current trial were excluded
 10 due to normal functioning mitochondria.

11

12 Measurement of *in vivo* ATP_{max} provides a direct estimate of the capacity for
 13 mitochondrial phosphorylation, while other approaches use mitochondrial respiration as a
 14 surrogate for the capacity for ATP production [43]. Therefore, the increased ATP_{max}
 15 observed in this study and in previous work in aged mouse skeletal muscles could be due
 16 to: 1) increased capacity for flux through the electron transport system (ETS) and 2)
 17 improved coupling of oxidation (electron flux, oxygen consumption) to phosphorylation
 18 (ATP production) by the mitochondria (P/O) [14]. These two possibilities are not
 19 mutually exclusive and are both consistent with the hypothesis that ELAM reversibly
 20 binds to cardiolipin to stabilize the cristae structure in the inner mitochondrial membrane
 21 [23, 44]. ELAM (or SS-31) has been demonstrated to increase or protect maximum ETS
 22 flux in isolated mitochondria and permeabilized muscle fibers in the case of severe
 23 dysfunction in multiple models and human subjects associated with heart failure ,

1 ischemia-reperfusion , and disuse muscle atrophy. However, in aged mouse skeletal
2 muscle the increased ATP_{max} after 1 hour or 8 weeks of ELAM (SS-31) treatment was not
3 associated with increased state 3 respiration in permeabilized muscle fibers [14, 26]. It is
4 worth noting that there was also no decrease in state 3 respiration comparing young to old
5 in these studies despite the significant decline in ATP_{max} with age, suggesting there is a
6 disconnect between maximum rates of respiration measured under saturating substrates
7 and optimal conditions *ex vivo* and maximum ATP production measured under
8 physiological conditions *in vivo*. In humans there is a significant correlation between
9 ATP_{max} and state 3 respiration in permeabilized fibers and in young and old skeletal
10 muscles, although *in vivo* ATP_{max} explained only about half of the variation in state 3
11 respiration in the older adult subjects. These results suggest increased maximum ETS
12 flux may not fully explain the improved ATP_{max} with ELAM treatment. Recent work also
13 indicates the ELAM directly interacts with mitochondrial proteins involved in substrate
14 supply to the ETS and phosphorylation of ADP to ATP[45] raising the possibility that
15 ELAM could both enhance substrate supply to the ETS and directly affect the
16 phosphorylation system in aged mitochondria.

17

18 The lack of an effect of ELAM on the coupling of oxidative phosphorylation (P/O) at rest
19 (**Supplemental Methods, Table S4**) in this study, despite selection of subjects with low
20 P/O, indicates that changes in the P/O measured under resting conditions is not an
21 important factor in the improved ATP_{max} observed in this study. The coupling between
22 oxygen consumption and ATP production (P/O) decreases with age in mouse and human
23 skeletal muscle [29]. In aged mice P/O increased with ELAM (SS-31) treatment 1 hour

1 after a single dose and after 8 weeks of continuous treatment [14, 26]. It is important to
2 note that *in vivo* P/O is measured under resting conditions where membrane potential is
3 high, while ATP_{max} is measured under high flux conditions and lower membrane
4 potential. Since membrane potential is a key driver of unregulated proton leak across the
5 mitochondrial inner membrane and proton leak is an important mechanism underlying
6 reduced coupling, the P/O is expected to increase as the flux through the ETS increases
7 as has been demonstrated in isolated mitochondria [46]. Therefore, a lower P/O measured
8 under resting conditions may not necessarily have a large impact on ATP production at
9 the high ETS flux rates near ATP_{max}. This argument and the lack of an effect of ELAM
10 on P/O in this study suggests that mitochondrial coupling is not the primary driver of the
11 increased ATP_{max} observed in this study. However, this does leave open the possibility
12 that there is a defect in the phosphorylation system (e.g. ADP/ATP exchange, ATPase
13 function) that impairs the coupling of respiration to ATP production as the mitochondria
14 approach maximum capacity. If ELAM treatment led to reversal of hypothetical
15 dysfunction in the ANT or ATPase this could have the effect of increasing ATP_{max}
16 without a large effect on state 3 respiration. In support of this possibility is a new study
17 using chemical cross linking with mass spectrometry (XL-MS) to demonstrate that
18 ELAM directly interacts with both the ANT and F1F0 ATPsynthase in skeletal muscle
19 mitochondria from aged mice [45]. However, the functional effects of these direct protein
20 interactions remain to be tested.

21

22 The rapid increase in ATP_{max} after a 2-hour ELAM infusion agrees with the immediate
23 effect of ELAM treatment on the same measure in the hindlimb of aged mice 1 hour after

1 treatment [14]. Such a fast mitochondrial response is apparent in isolated organ models of
 2 disease after ELAM treatment [47]. In comparison, weeks to months are required to
 3 achieve a response with treatments that activate mitochondrial biosynthesis pathways.
 4 For example, an oral dose of a SIRT1 activator designed to activate mitochondrial
 5 biogenesis in older adult subjects involved a 21-day treatment and resulted in a trend
 6 toward improved oxidative phosphorylation capacity [48]. In contrast to building new
 7 mitochondria, the rapid response in ATP_{max} in old, but not in young muscle of mice,
 8 suggests that ELAM treatment repaired a dysfunction that quickly raised mitochondrial
 9 ATP supply [14]. A mechanism of action of ELAM that includes both direct protein
 10 interactions and association with cardiolipin to alter membrane structure resulting in
 11 improved ETC function and mitochondrial oxidative phosphorylation capacity is
 12 consistent with these findings.

13

14 Despite the effect on ATPmax, the rise in exercise tolerance did not achieve statistical
 15 significance in ELAM versus placebo groups on the infusion day (**Figure 4**, $P=0.16$
 16 **Supplemental Table S5**). However, a significant rise was found between ELAM versus
 17 placebo with two additional days of testing (one day and one week post-infusion) in an
 18 ANOVA test ($P<0.04$). Both animal and human studies have demonstrated improvement
 19 in exercise tolerance with ELAM many days after infusion with daily doses. Greater
 20 6MWT distance was found in patients with genetic mitochondrial disease and impaired
 21 mobility after 5 daily infusions at the dose used in this study [28]. Similarly, old mice
 22 showed increased endurance (running time to fatigue) on day 8 after daily treatment and
 23 after 8 weeks of continuous treatment [14].

1

2 This study was originally powered to detect a difference in the effect of treatment on
3 mitochondrial energetics as the primary endpoint. As a result, the study was
4 underpowered to detect an effect on muscle fatigue resistance based on the FTI/MVC
5 measure. In a post-hoc analysis where the number of contractions, instead of FTI, was
6 used to assess muscle fatigue the ELAM treatment increased muscle fatigue resistance on
7 day 7 (*see supplemental material for methods and Figure S4*). The absence of significant
8 improvement in muscle endurance despite the increased ATP_{max} immediately after
9 infusion suggests a disconnect between mitochondrial ATP_{max} and muscle performance
10 changes with ELAM treatment in older adult human muscle. The direct effects on the
11 mitochondria occurring rapidly, while improvements in muscle performance may take
12 longer to manifest and be due to downstream effects of mitochondrial function not
13 directly linked to ATP supply by the mitochondria.

14

15 The primary limitation to this clinical trial was the small sample size target of 20 subjects
16 per treatment group that was reduced to 18 per group with a complete ATP_{max} dataset
17 due technical problems leading to missing data. This subject number achieved statistical
18 significance for a relative ATP_{max} change ($\Delta\%ATP_{max}$, $P=0.045$) with ELAM treatment,
19 but 25 subjects are needed to reach the threshold for the absolute change in ATP_{max} based
20 on power calculations derived from this study. A second limitation is the absence of data
21 on *ex vivo* functional data and redox status from isolated mitochondria or permeabilized
22 fibers. In the absence of the ability to specifically manipulate and interrogate specific
23 components of oxidative phosphorylation that are only possible *ex vivo* we are left to

1 speculate on the specific nature of the dysfunction with age and reversal with ELAM
2 treatment observed *in vivo* in this study.

3

4 **CONCLUSIONS**

5 Here, we demonstrate a pharmacological treatment that rapidly reverses mitochondrial
6 deficits of ATP production in skeletal muscle in healthy older adult subjects. Several new
7 insights come from this demonstration. First, the rise in ATP_{max} with a single infusion
8 identifies the mitochondria as a site of action of ELAM. Second, the speed of the effect
9 suggests that a rapidly reversible process in the mitochondria underlies this improvement.
10 This is in contrast to the biosynthesis and replacement of mitochondrial components that
11 underlie improvements in mitochondrial metabolism observed with exercise training.
12 Third, the decline in ATP_{max} to placebo levels after one week indicates a reversible
13 process. Thus, ELAM treatment provides new insight into the nature of mitochondrial
14 and muscle dysfunction with age. Most importantly, ELAM treatment holds promise as a
15 new therapy for the directly targeting mitochondrial dysfunction associated with age with
16 the potential to improve mobility limitations and disability that come with age and
17 disease.

18

1 **Conflict of interest statement:** Baback Roshanravan, David J. Marcinek, and Kevin E.
2 Conley have served as paid consultants for Stealth BioTherapeutics.

3 **Funding:** This work was supported by Stealth Biotherapeutics; National Institutes of
4 Health grants (5T32AG5738, UL1TR000423, 1S10OD016201, K23DK099442,
5 P01AG001751); the Department of Radiology and the Office of the Provost of the
6 University of Washington. The content of this publication is solely the responsibility of
7 the authors and does not necessarily represent the official views of the National Institutes
8 of Health.

9 **Acknowledgements:** We thank the volunteers who participated in this study for their
10 time and dedication as well as the contributions by Amy Good, Laura Ferrara, Jeff
11 Finman , Peter Rabinovich, Doug Weaver, Marc Bamberger, and James Carr. The
12 authors of this manuscript certify that they comply with the ethical guidelines for
13 publishing in the Journal of Cachexia, Sarcopenia, and Muscle [49].

14 **Author contributions:** Baback Roshanravan, David J. Marcinek, Kevin E. Conley, and
15 Stealth BioTherapeutics designed the research; Kevin E. Conley, Sophia Z. Liu, Amir S.
16 Ali, and Eric G. Shankland performed the research; Baback Roshanravan, John K.
17 Amory, and Thomas Robertson provided clinical oversight; Chessa Goss coordinated the
18 study; Kevin E. Conley, Sophia Z. Liu, David Marcinek, and Amir S. Ali analyzed data;
19 and Kevin E. Conley, Baback Roshanravan, and David J. Marcinek wrote the paper. As
20 first, second, and corresponding authors, Baback Roshanravan, Sophia Z. Liu, and David
21 J. Marcinek contributed equally to the study. Kevin E. Conley contributed to the
22 manuscript, but died prior to the manuscript's submission for publication.

23

24

1 REFERENCES

2

- 3 1. Guralnik, J.M., et al., *Lower-extremity function in persons over the age of 70*
4 *years as a predictor of subsequent disability*. N Engl J Med, 1995. **332**(9): p. 556-
5 61.
- 6 2. Roshanravan, B., et al., *Association of Muscle Endurance, Fatigability, and*
7 *Strength With Functional Limitation and Mortality in the Health Aging and Body*
8 *Composition Study*. J Gerontol A Biol Sci Med Sci, 2017. **72**(2): p. 284-291.
- 9 3. Korpelainen, R., et al., *Exercise capacity and mortality - a follow-up study of*
10 *3033 subjects referred to clinical exercise testing*. Ann Med, 2016. **48**(5): p. 359-
11 66.
- 12 4. Janssen, I., et al., *The healthcare costs of sarcopenia in the United States*. J Am
13 Geriatr Soc, 2004. **52**(1): p. 80-5.
- 14 5. Gonzalez-Freire, M., et al., *Reconsidering the Role of Mitochondria in Aging*. J
15 Gerontol A Biol Sci Med Sci, 2015. **70**(11): p. 1334-42.
- 16 6. Sorrentino, V., K.J. Menzies, and J. Auwerx, *Repairing Mitochondrial*
17 *Dysfunction in Disease*. Annu Rev Pharmacol Toxicol, 2017.
- 18 7. Kestenbaum, B., et al., *Impaired skeletal muscle mitochondrial bioenergetics and*
19 *physical performance in chronic kidney disease*. JCI Insight, 2020. **5**(5).
- 20 8. Coen PM, J.S., Distefano G, Amati F, et al. , *Skeletal muscle mitochondrial*
21 *energetics are associated with maximal aerobic capacity and walking speed in*
22 *older adults*. J Gerontol A Biol Sci Med Sci, 2012. **in press**.
- 23 9. Santanasto, A.J., et al., *The relationship between mitochondrial function and*
24 *walking performance in older adults with a wide range of physical function*. Exp
25 Gerontol, 2016. **81**: p. 1-7.
- 26 10. Choi, S., et al., *31P Magnetic Resonance Spectroscopy Assessment of Muscle*
27 *Bioenergetics as a Predictor of Gait Speed in the Baltimore Longitudinal Study of*
28 *Aging*. J Gerontol A Biol Sci Med Sci, 2016. **71**(12): p. 1638-1645.
- 29 11. Coen, P.M., et al., *Skeletal Muscle Mitochondrial Energetics Are Associated With*
30 *Maximal Aerobic Capacity and Walking Speed in Older Adults*. J Gerontol A Biol
31 Sci Med Sci.
- 32 12. Szeto, H.H., *First-in-class cardiolipin-protective compound as a therapeutic*
33 *agent to restore mitochondrial bioenergetics*. Br J Pharmacol. **171**(8): p. 2029-50.
- 34 13. Birk, A.V., et al., *Targeting mitochondrial cardiolipin and the cytochrome*
35 *c/cardiolipin complex to promote electron transport and optimize mitochondrial*
36 *ATP synthesis*. Br J Pharmacol. **171**(8): p. 2017-28.
- 37 14. Siegel, M.P., et al., *Mitochondrial-targeted peptide rapidly improves*
38 *mitochondrial energetics and skeletal muscle performance in aged mice*. Aging
39 Cell, 2013.
- 40 15. Mitchell, W., et al., *The mitochondria-targeted peptide SS-31 binds lipid bilayers*
41 *and modulates surface electrostatics as a key component of its mechanism of*
42 *action*. J Biol Chem, 2020. **295**(21): p. 7452-7469.

16. Allen, M.E., et al., *The cardiolipin-binding peptide elamipretide mitigates fragmentation of cristae networks following cardiac ischemia reperfusion in rats.* Commun Biol, 2020. **3**(389).
17. Mitchel, M., et al., *Molecular mechanism of action of mitochondrial therapeutic SS-31 (elamipretide): membrane interactions and effects on surface electrostatics.* BioRxiv.
18. Szeto, H.H., et al., *Protection of mitochondria prevents high-fat diet-induced glomerulopathy and proximal tubular injury.* Kidney Int, 2016. **90**(5): p. 997-1011.
19. Nickel, A., M. Kohlhaas, and C. Maack, *Mitochondrial reactive oxygen species production and elimination.* J Mol Cell Cardiol, 2014. **73**: p. 26-33.
20. Szeto, H.H. and P.W. Schiller, *Novel therapies targeting inner mitochondrial membrane--from discovery to clinical development.* Pharm Res, 2011. **28**(11): p. 2669-79.
21. Zhao, K., et al., *Mitochondria-targeted peptide prevents mitochondrial depolarization and apoptosis induced by tert-butyl hydroperoxide in neuronal cell lines.* Biochem Pharmacol, 2005. **70**(12): p. 1796-806.
22. Siegel, M.P., et al., *Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice.* Aging Cell, 2013. **12**(5): p. 763-71.
23. Brown, D.A., et al., *Reduction of early reperfusion injury with the mitochondria-targeting peptide bendavia.* J Cardiovasc Pharmacol Ther, 2014. **19**(1): p. 121-32.
24. Dai, W., et al., *Bendavia, a mitochondria-targeting peptide, improves postinfarction cardiac function, prevents adverse left ventricular remodeling, and restores mitochondria-related gene expression in rats.* J Cardiovasc Pharmacol, 2014. **64**(6): p. 543-53.
25. Sabbah, H.N., et al., *Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure.* Circ Heart Fail, 2016. **9**(2): p. e002206.
26. Campbell, M.D., et al., *Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice.* Free Radic Biol Med, 2019. **134**: p. 268-281.
27. Sakellariou, G.K., et al., *Mitochondrial ROS regulate oxidative damage and mitophagy but not age-related muscle fiber atrophy.* Sci Rep, 2016. **6**: p. 33944.
28. Karaa, A., et al., *Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy.* Neurology, 2018. **90**(14): p. e1212-e1221.
29. Amara, C.E., et al., *Mild mitochondrial uncoupling impacts cellular aging in human muscles in vivo.* Proc Natl Acad Sci U S A, 2007. **104**(3): p. 1057-62.
30. Amara, C.E., et al., *Mitochondrial function in vivo: spectroscopy provides window on cellular energetics.* Methods, 2008. **46**(4): p. 312-8.
31. Fried, L., C. Tangen, and J. Walston, *Frailty in older adults: evidence for a phenotype.* J of Gerontol, 2001. **56A**(3): p. M146-M156.
32. Roshanravan B, R.-C.C., Patel KV., *Association between physical performance and all-cause mortality in CKD.* J Am Soc Nephrol, 2013. **24**(5): p. 822-830.

- 1 33. Isoyama, N., et al., *Comparative associations of muscle mass and muscle strength*
2 *with mortality in dialysis patients*. Clin J Am Soc Nephrol, 2014. **9**(10): p. 1720-
3 8.
- 4 34. Newman, A.B., et al., *Strength, but not muscle mass, is associated with mortality*
5 *in the health, aging and body composition study cohort*. J Gerontol A Biol Sci
6 Med Sci, 2006. **61**(1): p. 72-7.
- 7 35. Conley, K., et al., *Elevated energy coupling and aerobic capacity improves*
8 *exercise performance in endurance trained elderly*. Exp Physiol.
- 9 36. Daubert, M.A., et al., *Novel Mitochondria-Targeting Peptide in Heart Failure*
10 *Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide*. Circ Heart
11 Fail, 2017. **10**(12).
- 12 37. Conley, K.E., S.A. Jubrias, and P.C. Esselman, *Oxidative capacity and ageing in*
13 *human muscle*. J Physiol, 2000. **526 Pt 1**: p. 203-10.
- 14 38. Ortega, J.O., et al., *Muscle force, work and cost: a novel technique to revisit the*
15 *Fenn effect*. J Exp Biol, 2015. **218**(Pt 13): p. 2075-82.
- 16 39. Claypool, S.M. and C.M. Koehler, *The complexity of cardiolipin in health and*
17 *disease*. Trends Biochem Sci, 2012. **37**(1): p. 32-41.
- 18 40. Houtkooper, R.H. and F.M. Vaz, *Cardiolipin, the heart of mitochondrial*
19 *metabolism*. Cell Mol Life Sci, 2008. **65**(16): p. 2493-506.
- 20 41. Wallace, D.C., W. Fan, and V. Procaccio, *Mitochondrial energetics and*
21 *therapeutics*. Annu Rev Pathol, 2010. **5**: p. 297-348.
- 22 42. Coen, P.M., et al., *Skeletal Muscle Mitochondrial Energetics Are Associated With*
23 *Maximal Aerobic Capacity and Walking Speed in Older Adults*. The journals of
24 gerontology. Series A, Biological sciences and medical sciences, 2012.
- 25 43. Campbell, M.D. and D.J. Marcinek, *Evaluation of in vivo mitochondrial*
26 *bioenergetics in skeletal muscle using NMR and optical methods*. Biochim
27 Biophys Acta, 2016. **1862**(4): p. 716-724.
- 28 44. Birk, A.V., et al., *The mitochondrial-targeted compound SS-31 re-energizes*
29 *ischemic mitochondria by interacting with cardiolipin*. J Am Soc Nephrol, 2013.
30 **24**(8): p. 1250-61.
- 31 45. Chavez, J.D., et al., *Mitochondrial protein interaction landscape of SS-31*. Proc
32 Natl Acad Sci U S A, 2020. **117**(26): p. 15363-15373.
- 33 46. Gnaiger, E., *Capacity of oxidative phosphorylation in human skeletal muscle: new*
34 *perspectives of mitochondrial physiology*. Int J Biochem Cell Biol, 2009. **41**(10):
35 p. 1837-45.
- 36 47. Szeto, H.H., et al., *Mitochondria-targeted peptide accelerates ATP recovery and*
37 *reduces ischemic kidney injury*. J Am Soc Nephrol, 2011. **22**(6): p. 1041-52.
- 38 48. Libri, V., et al., *A pilot randomized, placebo controlled, double blind phase I trial*
39 *of the novel SIRT1 activator SRT2104 in elderly volunteers*. PLoS One, 2012.
40 **7**(12): p. e51395.
- 41 49. von Haehling, S., et al., *Ethical guidelines for publishing in the Journal of*
42 *Cachexia, Sarcopenia and Muscle: update 2019*. J Cachexia Sarcopenia Muscle,
43 2019. **10**(5): p. 1143-1145.
- 44

Table 1. Baseline Characteristics of Study Population		
	Placebo (n=20)	Elamipretide (n=19)
Demographic		
Age (years, mean [$\pm$ SD])	69 (4)	68 (3.4)
Sex, Female (number [%])	7 (35.0)	11 (57.9)
White (number [%])	20 (100.0)	18 (94.7)
Clinical		
BMI (kg/m ² , mean [$\pm$ SD])	26.1 (2.8)	26.5 (4.3)
SBP (mm Hg, mean [$\pm$ SD])	124.3 (13)	121.1 (12.9)
Laboratory		
Sodium (mEq/dL, mean [$\pm$ SD])	137.7 (1.5)	137.5 (1.6)
Hemoglobin (gm/dL, mean [$\pm$ SD])	13.5 (0.9)	13.1 (0.9)
eGFR MDRD, (mL/[min $\cdot$ 1.73m ²], mean [$\pm$ SD])	81.5 (14.7)	82 (10.6)
Medications		
Statins (number [%])	5 (25.0)	2 (10.5)

1 BMI=body mass index; SBP=systolic blood pressure; eGFR MDRD=estimated
2 glomerular filtration rate.

3

1 **FIGURE LEGENDS**

2 **Figure 1: Study schema.** The primary endpoint for the study was change in ATP_{max} by
3 phosphorus magnetic resonance spectroscopy (³¹P MRS) after a 2-hour infusion
4 compared with baseline (screening). The secondary endpoints were a change in
5 mitochondrial coupling (P/O) and muscle force time integral (FTI) compared with
6 baseline (screening).

7
8 **Figure 2: Change in mitochondrial energetic capacity (ΔATP_{max}) with ELAM**
9 **treatment.** Change from baseline with ELAM treatment (post-infusion) and from
10 baseline 7 days post-infusion (day 7). A) Absolute change in ATP_{max}; B) % change
11 relative to baseline value. Error bars show SD. ELAM=elamipretide; PL=placebo.

12
13 **Figure 3: Change in mitochondrial coupling (ΔP/O) with ELAM treatment.** Change
14 from baseline with ELAM treatment (post-infusion) and from baseline 7 days post-
15 infusion (day 7). Error bars show SD. ELAM=elamipretide; PL=placebo.

16
17 **Figure 4: Change in muscle endurance test (ΔFTI/MVC) with ELAM treatment.**
18 Change from baseline with ELAM treatment post-infusion, from baseline 1 day post-
19 infusion (day 1) and from baseline 7 days post-infusion (day 7). Error bars show SD.
20 ELAM=elamipretide; PL=placebo.

21

Figure 1

Figure 3

Figure 4